ABI

59.04

-0.03%↓

CDI

438.8

-0.9%↓

DG

127.15

+0.75%↑

AD

40.45

+1%↑

HEIO

60.75

-0.65%↓

ABI

59.04

-0.03%↓

CDI

438.8

-0.9%↓

DG

127.15

+0.75%↑

AD

40.45

+1%↑

HEIO

60.75

-0.65%↓

ABI

59.04

-0.03%↓

CDI

438.8

-0.9%↓

DG

127.15

+0.75%↑

AD

40.45

+1%↑

HEIO

60.75

-0.65%↓

ABI

59.04

-0.03%↓

CDI

438.8

-0.9%↓

DG

127.15

+0.75%↑

AD

40.45

+1%↑

HEIO

60.75

-0.65%↓

ABI

59.04

-0.03%↓

CDI

438.8

-0.9%↓

DG

127.15

+0.75%↑

AD

40.45

+1%↑

HEIO

60.75

-0.65%↓

Search

Fluidra SA

Geschlossen

BrancheKonsumgüter defensiv

19.41 -0.26

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

19.24

Max

19.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

-9.6M

17M

Verkäufe

-38M

460M

KGV

Branchendurchschnitt

21.656

28.772

EPS

0.19

Dividendenrendite

3.23

Gewinnspanne

3.775

Angestellte

6,767

EBITDA

365M

460M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+43.08% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.23%

3.67%

Nächstes Ergebnis

6. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-741M

3.8B

Vorheriger Eröffnungskurs

19.67

Vorheriger Schlusskurs

19.41

Nachrichtenstimmung

By Acuity

50%

50%

53 / 131 Ranking in Consumer defensive

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Fluidra SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. März 2026, 23:47 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. März 2026, 22:55 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. März 2026, 21:51 UTC

Akquisitionen, Fusionen, Übernahmen

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. März 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. März 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. März 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. März 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. März 2026, 22:42 UTC

Market Talk
Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

23. März 2026, 22:42 UTC

Market Talk
Wichtige Nachrichtenereignisse

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. März 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. März 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. März 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. März 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. März 2026, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. März 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. März 2026, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. März 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. März 2026, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. März 2026, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. März 2026, 22:15 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. März 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. März 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. März 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. März 2026, 21:32 UTC

Ergebnisse

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. März 2026, 21:10 UTC

Wichtige Nachrichtenereignisse

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. März 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. März 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. März 2026, 20:50 UTC

Market Talk
Ergebnisse
Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Fluidra SA Prognose

Kursziel

By TipRanks

43.08% Vorteil

12-Monats-Prognose

Durchschnitt 26.87 EUR  43.08%

Hoch 31 EUR

Tief 21.5 EUR

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Fluidra SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

4

Buy

1

Halten

1

Sell

Technischer Score

By Trading Central

20.12 / 20.22Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

53 / 131 Ranking in Konsumgüter defensiv

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Fluidra SA

Fluidra, S.A., together with its subsidiaries, manufactures, distributes, and markets accessories and machinery for swimming-pools, irrigation and water treatment, and purification for residential and commercial pool market worldwide. The company provides basic pool fittings, which includes ladders, showers, pumps, valves, filters, heaters, grilles, water lighting, cleaning accessories, and others; robotic pool cleaners, pool covers, fire and water features, slides, springboards, and connected products; pool fittings spare parts; above-ground pools, and natural ponds and pools; and swim spas, saunas and steam baths, sensory showers, and Nordic baths. It also provides commercial pool and wellness water facilities for public use, including hotel and resort pools, water parks, municipal and competition pools, spa and wellness centers, fountains, lagoons, and aquariums; and develops turnkey aquatic projects. In addition, the company offers pool water treatment products; irrigation accessories for gardens; and manufactures and distributes high-end valves and accessories to build pool hydraulic circuits. It sells its products under the Astral Pool, Zodiac, Jandy, Polaris, GRE, Cepex, CTX Professional, Certikin, and Piscine Laghetto brands. The company was formerly known as Aquaria de Inv. Corp., S.L. and changed its name to Fluidra, S.A. in September 2007. Fluidra, S.A. was founded in 1969 and is headquartered in Sant Cugat del Vallès, Spain.
help-icon Live chat